Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16657397 | 0.89 | HTT (0.66) | HTTGAAALDH1A1RAB9AMAPT | |
| SCHEMBL29176301 | 0.87 | HTT (0.67) | HTTGAAALDH1A1RAB9AMAPT | |
| SCHEMBL30800007 | 0.87 | HTT (0.67) | HTTGAAALDH1A1RAB9AMAPT | |
| SCHEMBL4718392 | 0.83 | HTT (1.00) | HTTGAAALDH1A1RAB9AMAPT | |
| SCHEMBL16657412 | 0.79 | HTT (0.69) | HTTGAAALDH1A1RAB9AMAPT | |
| SCHEMBL16657410 | 0.78 | ALDH1A1 (0.74) | HTTGAAALDH1A1RAB9AMAPT | |
| SCHEMBL16657372 | 0.77 | ALDH1A1 (0.82) | HTTGAAALDH1A1RAB9AMAPT | |
| SCHEMBL9539274 | 0.77 | HTT (0.54) | HTTGAAALDH1A1RAB9AMAPT | |
| SCHEMBL16657368 | 0.77 | EGFR (0.55) | GAAMAPTEGFR | |
| SCHEMBL27728435 | 0.76 | ALDH1A1 (0.76) | HTTGAAALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9845321-B2 | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-19 | — | — | US | disclosed |
| US-9845321-B2 | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-19 | — | — | US | disclosed |
| EP-2864323-B1 | 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-19 | — | — | EP | disclosed |
| US-20160122346-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122346-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-05 | — | — | US | disclosed |
| US-20150111868-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSEN R&D IRELAND (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111868-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSEN R&D IRELAND (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122346-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, HELZ | HTT 2075/4885GAA 2216/4885ALDH1A1 2851/4885 |
| US-20150111868-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, HELZ | HTT 2075/4885GAA 2216/4885ALDH1A1 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.